Literature DB >> 2556119

Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals.

P F Watson1, M E Rose, S W Ellis, H England, S L Kelly.   

Abstract

Two azole resistant isolates of Saccharomyces cerevisiae carried mutations allelic to erg 3 and were blocked to differing degrees at the C5-6 desaturation step of ergosterol biosynthesis. When treated with the sterol 14 alpha-demethylation inhibitor fluconazole the wild-type sensitive strain accumulated lanosterol and 14 alpha-methyl-erogosta-8,24(28)-dien-3 beta, 6 alpha-diol (14-methyl-3,6 diol). The stringent desaturase mutant, A2, accumulated 14 alpha-methyl-8,24(28)-dien-3 beta-ol (14-methyl fecosterol) and lanosterol as the major sterol components when treated with fluconazole. Resistant isolate A3 accumulated 14-methyl-3,6-diol, 14-methyl fecosterol, and lanosterol and was only partially blocked at sterol C5-6 desaturation. We conclude that functional sterol C5-6 desaturase is required for the synthesis of 14-methyl-3,6-diol under conditions of azole inhibition. We present a new hypothesis for the mode of action of azole antifungals based on the inability of 14-methyl-3,6-diol to support growth, and suggest that growth can occur through utilisation of 14-methyl fecosterol, produced by a combination of azole inhibition and defective sterol C5-6 desaturation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556119     DOI: 10.1016/0006-291x(89)91792-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  69 in total

Review 1.  Fungal resistance.

Authors:  H Bernhardt; K Zimmermann; M Knoke
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  S279 point mutations in Candida albicans Sterol 14-α demethylase (CYP51) reduce in vitro inhibition by fluconazole.

Authors:  Andrew G S Warrilow; Jonathan G L Mullins; Claire M Hull; Josie E Parker; David C Lamb; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

3.  UPC2 is universally essential for azole antifungal resistance in Candida albicans.

Authors:  Erin M Vasicek; Elizabeth L Berkow; Stephanie A Flowers; Katherine S Barker; P David Rogers
Journal:  Eukaryot Cell       Date:  2014-03-21

Review 4.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and CDR1 Expression in Candida albicans.

Authors:  Andrew T Nishimoto; Qing Zhang; Brandon Hazlett; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 6.  Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Authors:  Steven L Kelly; Diane E Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

7.  Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

Authors:  A J Fischman; N M Alpert; E Livni; S Ray; I Sinclair; R J Callahan; J A Correia; D Webb; H W Strauss; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Investigation of the Sterol Composition and Azole Resistance in Field Isolates of Septoria tritici.

Authors:  T Joseph-Horne; D Hollomon; N Manning; S L Kelly
Journal:  Appl Environ Microbiol       Date:  1996-01       Impact factor: 4.792

9.  Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs.

Authors:  Yong-Qiang Zhang; Soledad Gamarra; Guillermo Garcia-Effron; Steven Park; David S Perlin; Rajini Rao
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

Review 10.  Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.

Authors:  Alan J Fischman; Nathaniel M Alpert; Robert H Rubin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.